Elicera Therapeutics is on the brink of launching its first clinical CAR T-cell study, CARMA, which aims to generate crucial data for its lead CAR T-cell candidate ELC-301 and the iTANK immune-boosting technology. It expect to be able to treat the first patients after summer and thus present interim data from the first dosage group with three patients at the turn of the year 2024/2025.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.445 SEK | -2.36% | +5.09% | -68.31% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-68.31% | 4.94M | |
+55.19% | 815B | |
+45.42% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+10.18% | 302B | |
+18.25% | 247B | |
+2.54% | 229B | |
+13.27% | 219B | |
+10.86% | 171B |
- Stock Market
- Equities
- ELIC Stock
- News Elicera Therapeutics AB
- Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA